5-substituted benzofurans as inhibitors of cytochrome P450 2D6
Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes. The compositions comprise 5-substituted benzofuran compounds having the formula I:
1. A compound represented by the formula:
wherein:
X is —N(D)—SO 2 —,
R′ is C 2 -C 6 alkylene optionally substituted by up to 3 substituents independently selected from the group consisting of C 1 -C 3 alkyl, alkylamido, alkylcarbamoyl, halo, nitro, cyano, S-alkyl, aralkyl and heteroaralkyl;
each D independently is selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, heteroaryl, heteroaralkyl and aralkyl;
R″ is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl-C 1 -C 6 -alkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, heteroaryl, heteroaralkyl or aralkyl, optionally substituted by up to 3 substituents independently selected from the group consisting of OH, O-alkyl, alkylamido, alkylcarbamoyl, halo, nitro, cyano, S-alkyl, aralkyl and heteroaralkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein each D is hydrogen or alkyl.
3. The compound according to claim 1 wherein R″ is C 1 -C 6 alkyl.
4. The compound according to claim 2 wherein R″ is C 1 -C 6 alkyl.
5. A pharmaceutical formulation comprising a pharmaceutically acceptable diluent, adjuvant or excipient, and a therapeutically effective amount of a compound according to claim 1 .